Biomarkers to define patients unlikely to derive benefit from endocrine therapy combined with CDK4/6 inhibitor are limited. Davis and colleagues performed a comprehensive biomarker analysis from a phase II clinical trial to evaluate whole-exome sequencing and genome-wide copy-number burden using circulating tumor DNA. These studies defined a subset of patients with high tumor mutational burden and elevated copy-number burden with shorter progression-free survival, and these assays offer opportunities as noninvasive tools for baseline tumor assessment and serial disease monitoring. Prospective studies are needed to define novel treatment strategies for patients with genomically complex disease.

The heterogeneity of HCC leads to a limited objective response rate to lenvatinib, and predicting the response to lenvatinib is clinically challenging. Bo and colleagues first performed this study to predict the response to lenvatinib monotherapy for unresectable HCC with machine learning radiomics. Significant differences in radiomics features were identified between responders and nonresponders treated with...

You do not currently have access to this content.